Table 3 Pooled results of endpoints.

From: Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review

 

No. of studies

No. of patients

Heterogeneity p

I2 (%)

Heterogeneity

Pooled results

(OR, 95% CI)

p (pooled analyses)

Egger’s p

Trimmed valuea

Overall survival

All studies

26

2741

<0.001

62.1

High

3.04 (2.28–4.06)

<0.001

0.046

2.32 (1.71–3.15)

Balanced

17

2279

<0.001

66.5

High

2.56 (1.79–3.66)

<0.001

0.154

 

RCTs

5

1172

0.288

19.9

Low

1.41 (1.02–1.95)

0.041

  

Targeting metastasesb

20

3146

<0.001

61.6

High

3.34 (2.40–4.66)

<0.001

0.080

2.41 (1.68–3.44)

Targeting primary diseaseb

6

1311

0.028

60.1

High

2.22 (1.21–4.08)

0.010

  

High metastatic burdenc

14

2074

0.017

49.9

Moderate

2.23 (1.56–3.20)

<0.001

0.674

 

Low metastatic burdenc

9

2154

<0.001

75.6

Very high

4.32 (2.45–7.59)

<0.001

  

NSCLC

11

1112

0.168

29.1

Moderate

3.14 (2.24–4.41)

<0.001

0.613

 

SCLC

2

130

0.184

43.2

Moderate

1.04 (0.34–3.24)

0.942

  

Prostate

2

1478

0.323

~0

Very low

1.87 (1.19–2.92)

0.006

  

Colorectal

3

602

<0.001

87.3

Very high

4.11 (0.91–18.5)

0.066

  

Progression-free survival

All studies

20

3116

<0.001

67.6

High

2.82 (1.96–4.06)

<0.001

0.001

1.59 (1.07–2.34)

Balanced

15

2559

0.001

61.0

High

2.32 (1.60–3.38)

<0.001

0.006

1.48 (0.99–2.22)

RCTs

7

1263

0.361

8.9

Very low

1.39 (1.09–1.80)

0.009

  

Targeting metastasesb

16

2010

0.001

62.0

High

3.34 (2.18–5.13)

<0.001

0.043

1.83 (1.14–2.96)

Targeting primary diseaseb

4

1106

0.155

42.8

Moderate

1.60 (0.99–2.59)

0.056

  

High metastatic burdenc

11

1111

0.827

~0.0

Very low

2.27 (1.67–3.09)

<0.001

0.04

1.99 (1.50–2.64)

Low metastatic burdenc

9

1961

<0.001

86.2

Very high

3.43 (1.70–6.96)

0.001

  

NSCLC

8

891

0.048

50.7

Moderate

3.28 (1.91–5.65)

<0.001

  

SCLC

2

130

0.276

15.8

Low

1.65 (0.54–5.03)

0.376

  

Prostate

5

1095

0.011

69.5

High

2.36 (1.15–4.82)

0.019

  

Colorectal

2

372

0.009

85.2

Very high

4.69 (0.97–22.8)

0.055

  
  1. OR odds ratio, CI confidence interval, RCT randomized controlled trial, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, HCC hepatocellular carcinoma.
  2. Pooled analysis was not performed for diseases with only one eligible study.
  3. aValues from Duval and Tweedie’s trim and fill method.
  4. bCategorized according to the intended goal of local consolidation therapy and primarily targeted lesions
  5. cStudies in which >80% of patients had a single metastasis or those that allowed patients with three or fewer metastases were regarded as low-burden studies; otherwise, studies that did not meet these criteria were regarded as high-burden studies (e.g., studies including patients with ≤5 metastases).
Back to article page